Talaris Therapeutics Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Talaris Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Talaris Therapeutics stock.
View analyst ratings for Talaris Therapeutics or view top-rated stocks.

Wall Street analysts have given Talaris Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Talaris Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Talaris Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, September 13th 2021.
View our earnings forecast for Talaris Therapeutics.

Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its quarterly earnings data on Sunday, June, 13th. The company reported ($1.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $1.04.
View Talaris Therapeutics' earnings history.

4 equities research analysts have issued 12 month price objectives for Talaris Therapeutics' stock. Their forecasts range from $21.00 to $35.00. On average, they expect Talaris Therapeutics' stock price to reach $29.25 in the next year. This suggests a possible upside of 111.8% from the stock's current price.
View analysts' price targets for Talaris Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Talaris Therapeutics include Revolution Medicines (RVMD), Instil Bio (TIL), Translate Bio (TBIO), Rubius Therapeutics (RUBY), Alector (ALEC), C4 Therapeutics (CCCC), bluebird bio (BLUE), Cortexyme (CRTX), Century Therapeutics (IPSC), Replimune Group (REPL), Valneva (VALN), Immunocore (IMCR), BioAtla (BCAB), Sangamo Therapeutics (SGMO) and REGENXBIO (RGNX).
View all of TALS's competitors.

(TALS) raised $150 million in an initial public offering on Friday, May 7th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO.

Talaris Therapeutics trades on the NASDAQ under the ticker symbol "TALS."

Talaris Therapeutics' quiet period expired on Wednesday, June 16th. Talaris Therapeutics had issued 8,825,000 shares in its public offering on May 7th. The total size of the offering was $150,025,000 based on an initial share price of $17.00. During the company's quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Shares of TALS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TALS stock can currently be purchased for approximately $13.81.

Talaris Therapeutics has a market capitalization of $570.49 million.

Talaris Therapeutics employs 82 workers across the globe.

The official website for Talaris Therapeutics is talaristx.com.

The company can be reached via phone at 502-398-9250.